Chronic Kidney Disease and Hyperkalemia: A Critical Clinical Challenge Requiring Proactive Management

Dr. Sandeep Arora,

Medical Director BBU & RDBU,

AstraZeneca, India

As medical professionals, we face an increasingly complex landscape in managing patients with chronic kidney disease (CKD), where hyperkalemia emerges as one of the most significant and recurrent complications. This electrolyte disorder not only threatens immediate patient safety but also creates substantial barriers to optimal guideline-directed medical therapy (GDMT).

The Epidemiological Reality

Chronic kidney disease affects approximately 850 million people globally, with hyperkalemia representing a disproportionately high burden in this population¹. While hyperkalemia occurs in only 2-3% of the general population, prevalence escalates dramatically to 40-50% among CKD patients, particularly those with stage 4-5 disease². The prevalence of CHK in India is estimated to be 13.24%.³ This stark disparity underscores the fundamental role of kidney dysfunction in potassium homeostasis.

The pathophysiology is multifactorial. As glomerular filtration rate declines below 30 mL/min/1.73m², the kidneys’ capacity for potassium excretion becomes progressively compromised. Simultaneously, metabolic acidosis, insulin resistance, and cellular potassium shifts further exacerbate hyperkalemia risk⁴. The situation becomes more complex when we consider that many CKD patients require renin-angiotensin-aldosterone system inhibitors (RAASi) for cardiovascular and renal protection, medications that inherently increase hyperkalemia risk.

The Recurrent Nature: A Clinical Conundrum

Perhaps the most challenging aspect of hyperkalemia in CKD is its recurrent nature. Recent real-world evidence demonstrates that patients experiencing an initial hyperkalemia episode have a 3-fold higher risk of subsequent episodes within 12 months⁵. This creates a vicious cycle where clinicians face the difficult choice between maintaining optimal RAASi therapy for long-term cardiovascular and renal benefits versus reducing or discontinuing these medications to manage acute hyperkalemia episodes.

Large-scale observational studies reveal concerning patterns: following a hyperkalemia event, 44-55% of patients experience RAASi dose reduction or discontinuation⁶. This therapeutic inertia has profound implications, as suboptimal RAASi dosing is associated with doubled mortality rates across all patient subtypes, including those with CKD stages 3-4⁷.

Clinical Implications and Cardiovascular Risk

The cardiovascular implications cannot be overstated. CKD patients already face a 100-500 fold increased risk of cardiovascular death compared to the general population, with this risk being age-dependent⁸. When hyperkalemia forces RAASi optimization compromises, we effectively compound this already elevated cardiovascular risk profile.

Recent registry data from the CHAMP-HF study illustrates this challenge: while 73% of heart failure patients with reduced ejection fraction receive ACE inhibitors, ARBs, or ARNIs, only 33% receive mineralocorticoid receptor antagonists (MRAs)⁹. The primary barrier? Hyperkalemia concerns and the associated risk of recurrent episodes.

Therapeutic Evolution and Future Directions

The therapeutic landscape has evolved significantly with the introduction of novel potassium binders. Both sodium zirconium cyclosilicate and patiromer have demonstrated efficacy in maintaining normokalemia while enabling RAASi optimization¹⁰. Current KDIGO guidelines now explicitly recommend considering potassium binders before reducing RAASi therapy, marking a paradigm shift toward maintaining optimal GDMT¹¹.

Moving forward, our clinical approach must prioritize early identification of hyperkalemia risk, proactive monitoring protocols, and strategic use of newer therapeutic options. The goal is clear: break the recurrent hyperkalemia cycle while preserving the cardiovascular and renal protective benefits of optimal medical therapy.

The evidence is compelling: hyperkalemia in CKD is not merely an electrolyte abnormality to correct, but a clinical barrier that demands sophisticated, individualized management strategies to optimize long-term patient outcomes.

References: 1. Kovesdy CP. Kidney Int. 2014;85(6):1303-1309. 2. Einhorn LM, et al. Clin J Am Soc Nephrol. 2009;4(9):1432-1439. 3. Talukdar R. Nephrology (Carlton). 2025 Jan;30(1):e14420. 4. Palmer BF, Clegg DJ. Mayo Clin Proc. 2016;91(11):1578-1588. 5. Thomsen RW, et al. Nephrol Dial Transplant. 2018;33:1610-1620. 6. Svensson MK, et al. ERA Congress 2024. 7. Epstein M, et al. Am J Manag Care. 2015;21(11):S212-S220. 8. Gansevoort RT, et al. Lancet. 2013;382:339-352. 9. Greene SJ, et al. J Am Coll Cardiol. 2018;72(4):351-366.10. Weir MR, et al. Clin J Am Soc Nephrol. 2017;12(7):1084-1093. 11. KDIGO CKD Work Group. Kidney Int. 2024;105(4S):S117-S314.

————————————————————————————————————————

Document Number: EM-10807; Approval Date: 10/3/2026; Expiration Date: 10/3/2028

Disclaimer: This article is for general awareness of the people and should not be construed as treatment advice. Please consult your doctor in case you have any symptoms or require further information/clarification. This public awareness initiative is supported by AstraZeneca Pharma India Limited.

“This article is part of the sponsored content programme.”

Published – March 12, 2026 12:57 pm IST